Literature DB >> 20839356

Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries.

Anikó Pósa1, Noemi Nyolczas, Rayyan Hemetsberger, Noemi Pavo, Ors Petnehazy, Zsolt Petrasi, Giuseppe Sangiorgi, Mariann Gyöngyösi.   

Abstract

OBJECTIVES: The aim of this preclinical study was to optimize the use of drug-eluting balloon (DEB) DIOR(2nd) (generation) by measurements of tissue and plasma paclitaxel concentrations in porcine coronary artery overstretch and prove efficacy in inhibition of neointimal growth without complementary use of stent.
BACKGROUND: The usually recommended DEB 60 sec inflation time causes prolonged ischemia and arterial injury.
METHODS: Tissue, plasma, and balloon surface concentrations of paclitaxel were measured in pigs 45 min and 12 hr after balloon inflation times of 15, 20, 30, 45, and 60 sec. Extent of neointimal hyperplasia was compared using DIOR(2nd) (generation) or noncoated balloon at two-week follow-up. Paclitaxel was replaced by fluorescent paclitaxel derivative in DEB and DES to demonstrate the distribution of the drug in arterial wall.
RESULTS: DIOR(2nd) (generation) DEB provided 29 ± 3 μM/L, 52 ± 6 μM/L, 196 ± 44 μM/L, 202 ± 36 μM/L, and 184 ± 59 μM/L paclitaxel to the vessel wall after 15, 20, 30, 45, and 60 sec of dilation, reaching plateau at 30 sec inflation time. Paclitaxel penetrated up to 2 mm tissue deepness. Measurable plasma paclitaxel level (45 ± 28 ng/mL) was found only after 60 sec balloon inflation time. At follow-up, the dilated arterial segment neointimal area and maximal neointimal thickness were significantly smaller with DIOR vs. uncoated balloon use. Fluorescence images of DIOR showed a homogenous distribution of the drug on the vessel, in contrast with DES.
CONCLUSION: Using the DIOR(2nd) (generation) DEB, a maximal balloon inflation time of 30-45 sec is optimal, reducing effectively the neointimal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20839356     DOI: 10.1002/ccd.22468

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  21 in total

1.  Opportunities and limitations of drug-coated balloons in interventional therapies.

Authors:  B Scheller
Journal:  Herz       Date:  2011-05       Impact factor: 1.443

Review 2.  Basic Concepts and Clinical Outcomes of Drug-Eluting Balloons for Treatment of Coronary Artery Disease: An Overview.

Authors:  C D Ramakrishna; Bhargav A Dave; Pankaj S Kothavade; Kajal J Joshi; Ashok S Thakkar
Journal:  J Clin Diagn Res       Date:  2017-06-01

3.  Coating and Pharmacokinetic Evaluation of Air Spray Coated Drug Coated Balloons.

Authors:  Emily A Turner; Marzieh K Atigh; Megan M Erwin; Uwe Christians; Saami K Yazdani
Journal:  Cardiovasc Eng Technol       Date:  2018-03-01       Impact factor: 2.495

4.  Reduced histologic neo in-stent restenosis after use of a paclitaxel-coated cutting balloon in porcine coronary arteries.

Authors:  Denise Traxler; Rayyan Hemetsberger; Andreas Spannbauer; Katrin Zlabinger; Alfred Gugerell; Dominika Lukovic; Ljubica Mandic; Noemi Pavo; Johannes Winkler; Mariann Gyöngyösi
Journal:  Histol Histopathol       Date:  2019-10-24       Impact factor: 2.303

5.  HPLC-MS/MS method for quantification of paclitaxel from keratin containing samples.

Authors:  Emily A Turner; Alexandra C Stenson; Saami K Yazdani
Journal:  J Pharm Biomed Anal       Date:  2017-03-10       Impact factor: 3.935

6.  Drug-eluting balloons with provisional bail-out or adjunctive stenting in de novo coronary artery lesions-a systematic review and meta-analysis.

Authors:  Smit Patel; Tatiana Svermova; Anne Burke-Gaffney; Richard G Bogle
Journal:  Cardiovasc Diagn Ther       Date:  2018-04

Review 7.  Drug eluting balloons for de novo coronary lesions - a systematic review and meta-analysis.

Authors:  Georg M Fröhlich; Alexandra J Lansky; Dennis T Ko; Olga Archangelidi; Rodney De Palma; Adam Timmis; Pascal Meier
Journal:  BMC Med       Date:  2013-05-08       Impact factor: 8.775

8.  Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction.

Authors:  Xiaojiao Hao; Damin Huang; Zhaoxia Wang; Jinchun Zhang; Hongqiang Liu; Yingmin Lu
Journal:  J Cardiothorac Surg       Date:  2021-06-21       Impact factor: 1.522

9.  Randomized trial of Legflow(®) paclitaxel eluting balloon and stenting versus standard percutaneous transluminal angioplasty and stenting for the treatment of intermediate and long lesions of the superficial femoral artery (RAPID trial): study protocol for a randomized controlled trial.

Authors:  Amine Karimi; Sanne W de Boer; Daniël A F van den Heuvel; Bram Fioole; Dammis Vroegindeweij; Jan M M Heyligers; Paul N M Lohle; Otto Elgersma; Rudolf P T Nolthenius; Jan Albert Vos; Jean-Paul P M de Vries
Journal:  Trials       Date:  2013-03-28       Impact factor: 2.279

10.  Human recombinant activated protein C-coated stent for the prevention of restenosis in porcine coronary arteries.

Authors:  Dominika Lukovic; Noemi Nyolczas; Rayyan Hemetsberger; Imre J Pavo; Aniko Pósa; Boris Behnisch; Gerhard Horak; Katrin Zlabinger; Mariann Gyöngyösi
Journal:  J Mater Sci Mater Med       Date:  2015-09-28       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.